Equities

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Amgen Inc grew revenues 6.14% from 21.66bn to 22.99bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 11.28% net income growth from 6.94bn to 7.72bn.
Gross margin81.94%
Net profit margin34.43%
Operating margin43.54%
Return on assets10.32%
Return on equity26.61%
Return on investment11.79%
More ▼

Cash flow in USDView more

In 2016, cash reserves at Amgen Inc fell by 903.00m. However, the company earned 10.35bn from its operations for a Cash Flow Margin of 45.04%. In addition the company used 8.66bn on investing activities and also paid 2.60bn in financing cash flows.
Cash flow per share13.37
Price/Cash flow per share12.78
Book value per share41.62
Tangible book value per share8.09
More ▼

Balance sheet in USDView more

Amgen Inc has a Debt to Total Capital ratio of 52.67%, a lower figure than the previous year's 111.78%.
Current ratio4.41
Quick ratio4.14
Total debt/total equity1.11
Total debt/total capital0.5267
More ▼

Growth rates in USD

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 26.58% and 13.06%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)1.91%
Div growth rate (5 year)48.17%
Payout ratio (TTM)39.00%
EPS growth(5 years)20.46
EPS (TTM) vs
TTM 1 year ago
11.69
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.